{"version":"1.0","provider_name":"FYB Financial Yearbook","provider_url":"https:\/\/www.fyb.de\/en\/","author_name":"Tatjana Anderer","author_url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/","title":"Gibson Dunn advises KKR on investment in Coriolis Pharma - FYB Financial Yearbook","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"hO3Og1W4Bc\"><a href=\"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-on-investment-in-coriolis-pharma\/\">Gibson Dunn advises KKR on investment in Coriolis Pharma<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.fyb.de\/en\/gibson-dunn-advises-kkr-on-investment-in-coriolis-pharma\/embed\/#?secret=hO3Og1W4Bc\" width=\"600\" height=\"338\" title=\"&#8220;Gibson Dunn advises KKR on investment in Coriolis Pharma&#8221; &#8212; FYB Financial Yearbook\" data-secret=\"hO3Og1W4Bc\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/10\/coriolis-pharma-web-thumbnail.webp","thumbnail_width":800,"thumbnail_height":400,"description":"Frank\u00adfurt, London and Munich \u2014 KKR Health Care Growth Fund II has made an invest\u00adment in German biophar\u00admaceu\u00adti\u00adcal rese\u00adarch and deve\u00adlo\u00adp\u00adment company Corio\u00adlis Pharma. As part of the tran\u00adsac\u00adtion, Corio\u00adlis Pharma will enter into a stra\u00adte\u00adgic growth part\u00adner\u00adship with Fron\u00adtier Bioso\u00adlu\u00adti\u00adons, a global phar\u00admaceu\u00adti\u00adcal services plat\u00adform newly formed by KKR and Flerie Invest AB. KKR\u2019s [&hellip;]"}